Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II study of HZ-A-018 in relapsed or refractory primary or secondary CNS lymphoma
CTR20210181Phase 2Active
- Sponsor
- Hezheng Pharma
- Start
- Apr 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of HZ-A-018 in primary central nervous system lymphoma (PCNSL), secondary central nervous system lymphoma (SCNSL), vitreoretinal lymphoma (PVRL), sponsored by Hezheng Pharma. Started Apr 2021; status: active.
02
Drugs
HZ-A-018
03
Conditions
primary central nervous system lymphoma (PCNSL)secondary central nervous system lymphoma (SCNSL)vitreoretinal lymphoma (PVRL)
Beyond the preview
Go deeper on CTR20210181.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20210181.